We are Fulfilling Unmet Needs in Pulmonary Medicine.

Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.

Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:

• Continued development of proprietary respiratory disease therapies

• Pursue regulatory pathways that reduce the time, costs and risks associated with product development

• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing

• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States

• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise

News & Events

Aradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26
[22SEP17]

Ladenburg Thalmann 2017 Healthcare Conference

Aradigm to Host KOL Call on Infection Management in Non-Cystic Fibrosis Bronchiectasis Patients
[18SEP17]

Aradigm Announces Upcoming Data Presentations in Non-Cystic Fibrosis Bronchiectasis at the European Respiratory Society (ERS) 2017 Annual Congress
[07SEP17]

Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculosis Mycobacterial (PNTM) Infections with Linhaliq
[15AUG17]

 More News >>